GlassScriptPhysician profile
Martin Dubravec
NPI 1114013711
$7,448.62
in general payments reported to CMS, 2019-2025
31 companies · $1,006 in 2025
The $1,006 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $774 · 2021: $1,338 · 2022: $1,331 · 2023: $1,159 · 2024: $999 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,122 · Education: $42.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,122.08 |
| Education | $42.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,861.23 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $963.16 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $625.50 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Csl Behring | $562.86 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Novartis Pharmaceuticals Corporation | $434.05 | 2019-2025 | |
| Genentech USA, INC. | $417.06 | 2019-2025 | Xolair |
| Genzyme Corporation | $337.89 | 2019-2024 | |
| Blueprint Medicines Corporation | $306.89 | 2021-2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $256.68 | 2019-2023 | Dupixent |
| Electromed, INC. | $222.61 | 2021-2025 | Smartvest |
| Amgen INC. | $197.08 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $169.70 | 2019-2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $162.46 | 2021-2022 | |
| Kaleo, INC. | $129.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.76 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $102.30 | 2019-2025 | |
| Grifols USA, LLC | $94.97 | 2021-2023 | Xembify |
| Sunovion Pharmaceuticals INC. | $93.76 | 2019 | |
| Biocryst US Sales Co., LLC | $84.92 | 2021-2023 | Orladeyo |
| Aimmune Therapeutics, INC. | $55.53 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $51.01 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $39.75 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $36.30 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.17 | 2025 | Xhance |
| Cycle Pharmaceuticals INC | $17.38 | 2025 | Sajazir |
| Alnylam Pharmaceuticals INC. | $16.71 | 2022 | |
| Horizon Therapeutics Plc | $16.40 | 2021 | |
| Abbvie INC. | $16.15 | 2021 | |
| Exact Sciences Corporation | $15.53 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $13.33 | 2021 | |
| Shire North American Group INC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Dubravec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.